Product
Calquence
Aliases
CALQUENCE
Name
CALQUENCE
FDA Approved
Yes
1 clinical trial
1 organization
1 drug
1 indication
1 document
Indication
Chronic Lymphocytic LeukemiaDrug
acalabrutinibClinical trial
A Non-interventional, Prospective, Open-label, Observational Study Evaluating the Effectiveness and Safety of Acalabrutinib (Calquence®) in Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Direct Oral Anticoagulation (DOAC).Status: Recruiting, Estimated PCD: 2025-10-12
Document
DailyMed Label: CALQUENCEOrganization
AstraZeneca Pharmaceuticals LP